Mahwah-based Glenmark Pharmaceuticals plans to expand its Paramus facility by 35,000 square feet, a 20 percent increase over the 161,000-square-foot facility.
The expanded facility will house 115 employees with room for additional growth, according to a company spokesperson.
The expansion is part of the growth that Fred Grossman, the company’s chief medical officer, discussed with NJBIZ in June. At that time, Grossman said that the biopharmaceutical company would seek to add to its staff by taking advantage of company layoffs made last year by some of the state’s big drug makers, including Novartis. In May, Novartis laid off about 250 people from its East Hanover and Princeton locations.
“We’re going to need really top talent for our innovative pipeline of research and development,” Grossman told NJBIZ in June. “And, a lot of the time, we get that from drawing people from big pharmaceutical companies.”
“Glenmark currently has seven proprietary clinical drug candidates in development in three core areas: oncology, dermatology and respiratory medicine,” a company spokesperson said in an email. “These pipeline therapeutics have advanced substantially over the past year. The new and expandable facility will give Glenmark the space it needs to support these clinical advances and the anticipated filing of a New Drug Application in early 2018.”